Prognostic Significance and Clinical Correlations of Myeloid Mutations in Myelofibrosis Based on Their Functional Class
Background: In addition to the driver mutations JAK2, CALR and MPL, patients (pts) with primary myelofibrosis (PMF) may also express mutations in a number of genes frequently associated with myeloid neoplasms. These genes encode regulators of chromatin modification and DNA methylation, RNA splicing...
Gespeichert in:
Veröffentlicht in: | Blood 2023-11, Vol.142 (Supplement 1), p.4533-4533 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: In addition to the driver mutations JAK2, CALR and MPL, patients (pts) with primary myelofibrosis (PMF) may also express mutations in a number of genes frequently associated with myeloid neoplasms. These genes encode regulators of chromatin modification and DNA methylation, RNA splicing and transcription, as well as oncogenes and signal transduction. In pts with PMF, including those with prefibrotic (pre-)-PMF, selected mutations were shown to deserve prognostic relevance, and led to the development of molecular integrated, or exclusive, scores (such as MIPSS70, MIPSS70-plus, GIPSS and others).
Aim: The aim of the study was to correlate the type of mutations, clustered in relation to their known functional classes, with hematological and clinical correlates, and outcome in a large population of molecularly annotated pts with PMF.
Patients and Methods: All pts with a confirmed ICC 2022 diagnosis of PMF from the database at CRIMM (Florence), for whom mutation analysis of a panel of 40 myeloid neoplasm-associated genes performed by NGS (Oncomine, ThermoFisher) was available, were included in the study. Pts were stratified in 6 categories based on known function of mutated gene: spliceosome (cat. 1: SF3B1, U2AF1, SRSF2, ZRSR2), DNA methylation gene (cat. 2: TET2, DNMT3A, IDH1, IDH2, SETBP1), histone modification gene (cat. 3: ASXL1, EZH2), RAS pathway (cat. 4: NRAS, KRAS, CBL, NF1, PTPN11), transcription factor (cat. 5: RUNX1, NFE2, TP53) and “other” gene mutations (cat. 6: LNK/SH2B3).
Results: A total of 286 pts with at least 1 myeloid neoplasm-associated gene mutation were included (110 prePMF, 38.5%; 176 overt PMF, 61.5%). Of these, 69 have mutations in spliceosome genes, 81 in DNA methylation genes, 95 in histone modification genes, 19 in the RAS pathway, 13 in transcription factor genes and 9 in “other” gene category.
Analysis of clinical characteristics (Table) showed that Cat. 1 pts were significantly older (80.6% aged >60y, P=0.003), no difference regarding gender. There was no difference in blood counts but circulating blasts >1%, that were higher in cat 3 and 1 compared to the others (P=0.009). A G3 fibrosis was more common in cat 3 and 5 (43.5% and 50%, p |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2023-189571 |